AKTX

Akari Therapeutics PLC
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$17.02M
P/E Ratio
—
EPS
$0.00
Beta
1.47
52W High
$29.32
52W Low
$3.02
50-Day MA
$9.14
200-Day MA
$8.96
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00

About Akari Therapeutics PLC

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA$-12.08M
Operating Margin0.00%
Return on Equity-140.10%
Return on Assets-19.10%
Revenue/Share (TTM)$0.00
Book Value$10.62
Price-to-Book0.86
Price-to-Sales (TTM)478368.50
EV/Revenue400346.36
EV/EBITDA-0.06
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$2.29M
Float$1.43M
% Insiders16.32%
% Institutions11.32%

Historical Volatility

HV 10-Day
149.53%
HV 20-Day
154.10%
HV 30-Day
146.38%
HV 60-Day
121.59%
HV Rank
—

Volatility is currently expanding

Analyst Ratings

Consensus ($25.50 target)
1
Strong Buy
1
Buy

Latest News

Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform

Initiated GLP toxicology studies of lead TROP2-targeted ADC AKTX-101 to enable planned Phase 1 trial in mid-2027 New preclinical findings demonstrate anti-tumor activity in urothelial cancer models resistant to currently approved ADC therapies, reinforcing the potential of novel PH1 payload for patients relapsing on current ADC therapies Collaboration with Whitehawk Therapeutics on novel dual payloads emphasizes PH1 payload's strategic partnering opportunities Strengthened balance sheet with approximately $3 million in proceeds from warrant exercises, ending the quarter with $5.7 million in cash TAMPA, Fla. and LONDON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today reported financial results for the third quarter ended September 30, 2026, and highlighted significant progress advancing its proprietary PH1 payload platform toward Phase 1 clinical development.

GlobeNewsWire11/12/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AKTX and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/13/2026